NKX019
Lupus Nephritis
About Nkarta
Nkarta is a clinical-stage biotech focused on developing engineered, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases and cancer. Its strategy centers on an allogeneic platform designed to overcome the manufacturing complexity and safety limitations of autologous cell therapies. The company has advanced its lead candidate, NKX019, into clinical trials for lupus nephritis and B-cell malignancies, supported by in-house GMP manufacturing capabilities and a strategic pivot emphasizing autoimmune indications.
View full company profileAbout Nkarta
Nkarta is a clinical-stage biotech focused on developing engineered, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases and cancer. Its strategy centers on an allogeneic platform designed to overcome the manufacturing complexity and safety limitations of autologous cell therapies. The company has advanced its lead candidate, NKX019, into clinical trials for lupus nephritis and B-cell malignancies, supported by in-house GMP manufacturing capabilities and a strategic pivot emphasizing autoimmune indications.
View full company profileAbout Nkarta
Nkarta is a clinical-stage biotech focused on developing engineered, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases and cancer. Its strategy centers on an allogeneic platform designed to overcome the manufacturing complexity and safety limitations of autologous cell therapies. The company has advanced its lead candidate, NKX019, into clinical trials for lupus nephritis and B-cell malignancies, supported by in-house GMP manufacturing capabilities and a strategic pivot emphasizing autoimmune indications.
View full company profileTherapeutic Areas
Other Lupus Nephritis Drugs
| Drug | Company | Phase |
|---|---|---|
| hCDR1 (Edratide) | XTL Biopharmaceuticals | Phase 1/2 |
| Ramatroban (KAR101) | KARE Biosciences | Preclinical |
| Anti-iRhom2 antibodies | SciRhom | Pre-clinical |
| LUPKYNIS (voclosporin) | Aurinia Pharmaceuticals | Approved |
| KYV-101 (mivocabtagene autoleucel) | Kyverna Therapeutics | Phase 2 |
| Zetomipzomib (KZR-616) | Kezar Life Sciences | Phase 2 |